This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
I'm LongbridgeAI, I can summarize articles.UBS analyst Nicolas Gaudois initiated coverage on SK Hynix Inc (NASDAQ:SKHY) with a Buy rating and set a price target of $204. This follows SK Hynix's closing price of $126.79 on Wednesday. The article also notes other analyst initiations, including Deutsche Bank's Hold rating for Kymera Therapeutics at $120 and Rodman & Renshaw's Buy rating for Actuate Therapeutics at $6.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Deutsche Bank analyst David Hoang initiated coverage on Kymera Therapeutics Inc (NASDAQ:KYMR) with a Hold rating and announced a price target of $120. Kymera Therapeutics shares closed at $105.25 on Wednesday. See how other analysts view this stock.
- UBS analyst Nicolas Gaudois initiated coverage on SK Hynix Inc – ADR (NASDAQ:SKHY) with a Buy rating and announced a price target of $204. SK Hynix closed at $126.79 on Wednesday. See how other analysts view this stock.
- Rodman & Renshaw analyst Michael G. King Jr. initiated coverage on Actuate Therapeutics Inc (NASDAQ:ACTU) with a Buy rating and announced a price target of $6. Actuate Therapeutics shares closed at $1.08 on Wednesday. See how other analysts view this stock.
Considering buying SKHY stock? Here’s what analysts think:
Photo via Shutterstock